| Document |
Document Title |
|
WO/2004/089876A1 |
Compounds of formula (I) or pharmaceutically acceptable derivatives thereof, and their use as pharmaceuticals, particularly as p38 kinase inhibitors.
|
|
WO/2004/089885A1 |
The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.
|
|
WO/2004/087655A1 |
The invention relates to a novel diphenyl azetidinone, to a method for its production, to medicaments containing said compound and to the use of the latter. The invention relates to the compound of general formula (I), in addition to its...
|
|
WO/2004/087650A2 |
A novel process is provided for the preparation of chiral beta-amino acid amide inhibitors of the dipeptidyl peptidase-IV and the useful intermediates obtained therein. The products resulting from the instant process are inhibitors of di...
|
|
WO/2004/083166A1 |
The invention provides processes by which (R)-3-[4- (trifluoromethyl)phenylamino]pentanamide derivatives useful as intermediates of drugs, particularly, cholesteryl ester transfer protein (CETP) inhibitor can be easily and simply produce...
|
|
WO/2004/081643A1 |
A light source for a Liquid Crystal Display ('LCD') device uses a conventional light source (42) to create a parallel beam which is directed to a first lenslet array (46), producing a plurality of beams, each of which is directed to a po...
|
|
WO/2004/081002A1 |
The present invention provides substituted azetidinone compounds of formula (I) formulations and processes for preparing the same which can be useful to vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesi...
|
|
WO/2004/071454A2 |
Novel azetidine-derived inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of such inhibitors, and novel methods of treating medical conditions are provided. The novel...
|
|
WO/2004/072025A2 |
The invention relates to N-arylheterocycles and the physiologically-acceptable salts and physiologically-functional derivatives thereof. Compounds of formula (I), where the groups have the given meanings, the N-oxides and the physiologic...
|
|
WO/2004/069793A2 |
The present invention relates to modulators of the calcium sensing receptor having the formula I (I) wherein Ar1, X, n, R1, R2, R3, and Q are as defined herein.
|
|
WO/2004/058735A2 |
Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders. The compounds have the following structure (I) including stereoisomers, prodrugs, and pharmaceuticall...
|
|
WO/2004/058149A2 |
The present invention encompasses compounds of Formula (I): as well as the pharmaceutically acceptable salts and hydrates thereof. The compounds are useful for treating immune mediated diseases and conditions, such as bone marrow, organ ...
|
|
WO/2004/056766A1 |
The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.
|
|
WO/2004/052839A1 |
The invention relates to isophtalic acid derivatives, a method for the preparation thereof and the use of said derivatives for producing drugs for treating and/or preventing diseases, in particular cardiovascular diseases of a human bein...
|
|
WO/2004/050613A2 |
This invention provides 2-substituted-propenamide derivatives and their compositions for the treament of hepatitis B virus and/or hepatitis D virus.
|
|
WO/2004/048326A1 |
A preventive/therapeutic agent for respiratory diseases which contains as an active ingredient either a compound represented by the following formula (I): (I) wherein A is a group represented by L-W [L is a bond or CH2 and W is oxygen, S...
|
|
WO/2004/043940A1 |
The present invention is directed to phenylalanine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme ('DP-IV inhibitors') and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptid...
|
|
WO/2004/043939A1 |
Disclosed is a compound having the formula (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and so...
|
|
WO/2004/043973A1 |
A novel intermediate which is for use in efficiently producing a 1β-methylcarbapenem compound for oral administration; and a process for producing the intermediate. The process, which is for producing a novel β-lactam compound represen...
|
|
WO/2004/042351A2 |
The present invention is directed to compounds of the formula (I): (wherein R¿1?, R¿2?, R¿3?, R¿4?, R¿5?, R¿6?, W, X, Z, m and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, thes...
|
|
WO/2004/041795A1 |
Novel inhibitors of dipeptidyl peptidase IV (DPP IV), pharmaceutical compositions comprising therapeutically effective amounts of novel inhibitors of DPP IV, and novel methods of treating medical conditions are provided. The novel inhibi...
|
|
WO/2004/035538A1 |
The present invention is directed to an improved process for synthesizing azetidine-3-carboxylic acid, comprising triflating diethylbis(hydroxymethyl)malonate followed by azetidine ring-formation by intramolecular cyclization using an am...
|
|
WO/2004/035539A1 |
A process for producing a compound represented by the following formula (XI) [wherein R2 represents an in vivo degradable, easily removable group and R4 represents 1-(1,3-thiazolin-2-yl)azetidin-3-yl or pyrrolidin-2-on-4-yl], which is us...
|
|
WO/2004/035540A1 |
A compound represented by the following general formula (1) (wherein R represents a group which is easily hydrolyzed in vivo and removed) or its salt. This compound can be used in producing a carbapenem antibacterial agent of the prodrug...
|
|
WO/2004/033442A2 |
Disclosed are compounds of formula having utility as intermediates in the preparation of paclitaxel, taxotere and analogs thereof, and intermediates thereof.
|
|
WO/2004/031137A1 |
Compounds of formula (I) inhibit the processing of APP by gamma-secretase, and hence are useful in treatment of Alzheimer's disease.
|
|
WO/2004/026824A1 |
The present invention is directed to a process for preparing intermediates that are useful to prepare certain antibacterial N-formyl hydroxylamine compounds which are peptide deformylase inhibitors. The process makes use &agr β-lactam i...
|
|
WO/2004/024702A1 |
The invention relates to carboxamide compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1, R2, R3, and k have the meanings indicated in claim 1. The invention also relates to methods for producing said ...
|
|
WO/2004/018414A2 |
The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein X=NH Y=CO, CS, -C(=N-CN) or X and Y together form an alkene, or C3-C5 cycloalkyl; R1 is -COOH; R2 is an electron withdrawing g...
|
|
WO/2004/014960A2 |
The present invention provides novel fluorine-containing copolymers which comprise at least one fluorinated olefin, at least one polycyclic ethylenically unsaturated monomer with a fused 4-membered heterocyclic ring and, optionally, othe...
|
|
WO/2004/007444A2 |
Novel N-hydroxyamide derivatives are disclosed. These N-hydroxyamide derivatives inhibit UPD-3O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme present in gram negative bacteria and are therefore useful as antimicrobial...
|
|
WO/2004/007446A1 |
A compound represented by the following formula (I), which has excellent dipeptidyl peptidase IV inhibitory activity; and a therapeutic agent which, based on the activity, is highly effective against insulin dependent diabetes (type 1 di...
|
|
WO/2004/005247A1 |
Compounds of formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as cholesterol absorption inhibitors for the treatment of hy...
|
|
WO/2004/002491A1 |
The present invention relates to novel cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2004/000803A1 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5 and R6 are defined as cited, in addition to their physiologically compatible salts. The compounds are suitable for use e.g. as hypolipidaemics.
|
|
WO/2004/000804A1 |
Disclosed are ring-substituted diphenyl azetidinones of formula I, a method for the production thereof, medicaments containing said compounds, and the use thereof for treating hyperlipidemia, arteriosclerosis, and hypercholesterolemia.
|
|
WO/2004/000805A1 |
The invention relates to compounds of formula (I), in which R1, R2, R3, R4, R5 and R6 are defined as cited, in addition to their physiologically compatible salts. The compounds are suitable for use e.g. as hypolipidaemics.
|
|
WO/2003/106390A1 |
A polymerisation inhibitor comprising a non-hindered cyclic hydroxylamine either alone or in combination with an additional inhibitor.
|
|
WO/2003/101956A1 |
There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defin...
|
|
WO/2003/101423A1 |
According to the present invention there is provided an immediate release pharmaceutical formulation comprising, as active ingredient, a compound of formula (I), wherein R¿1? represents C?1-2#191 alkyl substituted by one or more fluoro ...
|
|
WO/2003/101424A1 |
A modified release pharmaceutical composition comprising, as active ingredient, a compound of formula (I), wherein R¿1? represents C?1-2#191 alkyl substituted by one or more fluoro substituents;R¿2? represents hydrogen, hydroxy, methox...
|
|
WO/2003/101957A1 |
There is provided pharmaceutically-acceptable acid addition salts of compounds of formula (I), wherein R1 represents C1-2 alkyl substituted by one or more fluoro substituents; R2 represents C1-2 alkyl; and n represents 0, 1 or 2, which s...
|
|
WO/2003/101958A2 |
The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV, pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associa...
|
|
WO/2003/086388A1 |
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for t...
|
|
WO/2003/082190A2 |
Novel compounds of structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of ...
|
|
WO/2003/080053A1 |
88thods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula (Chemical formula should be inserted here as it appears on abstract in paper form...
|
|
WO/2003/080571A1 |
It is intended to provide a process for selectively obtaining an intermediate in synthesizing a desired carbapenem-type antibacterial agent having a methyl group at the 1’-β-position in a short period and at a high yield under mild co...
|
|
WO/2003/078376A1 |
A NK1 antagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough.
|
|
WO/2003/077907A1 |
Compounds of formula (I) in free or salt form, wherein Ar, X, Y, R1, R2, R3, R5, m, n, p, and q have the meanings as indicated in the specification, are useful for treating conditions mediated by CCR3. Pharmaceutical compositions that co...
|
|
WO/2003/075853A2 |
The present application describes modulators of MCP-1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of rheumatoid arthritis, multiple sclerosis, atherosclerosis, asthma, restinosis, organ tra...
|
